Defining a prognostic marker panel for patients with ovarian serous carcinoma effusion

Human Pathology

Volumn 44, Issue 11, 2013, Pages 2449-2460

  Davidson, Ben ^a,b   Smith, Yoav ^c   Nesland, Jahn M ^a,b   Kærn, Janne ^a   Reich, Reuven ^d   Tropè, Claes G ^a,b  

^a OSLO UNIVERSITY HOSPITAL   (Norway)

^b UNIVERSITY OF OSLO   (Norway)

^c HEBREW UNIVERSITY   (Israel)

^d HEBREW UNIVERSITY OF JERUSALEM   (Israel)

Author keywords

Biomarkers; Immunohistochemistry; Ovarian carcinoma; Serous effusions; Survival

Indexed keywords

ACTIVATOR PROTEIN 2 GAMMA; ANTINEOPLASTIC AGENT; APOLIPOPROTEIN E; BRAIN PROTEIN; CALVASCULIN; CLAUDIN 1; CLAUDIN 3; CLAUDIN 7; CYCLOOXYGENASE 2; FAS ANTIGEN; FATTY ACID SYNTHASE; HEAT SHOCK PROTEIN 90; HEPARANASE; HIGH MOBILITY GROUP A2 PROTEIN; HISTONE DEACETYLASE 1; HLA ANTIGEN; HUMAN LEUKOCYTE ANTIGEN G; KALLIKREIN; KALLIKREIN 4; MAMMALIAN TARGET OF RAPAMYCIN; NUCLEUS ACCUMBENS 1 PROTEIN; P21 ACTIVATED KINASE 1; PACLITAXEL; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PLATINUM DERIVATIVE; SOMATOMEDIN B; STAT5B PROTEIN; SURVIVIN; TUMOR MARKER; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; CANCER ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER PATIENT; CANCER PROGNOSIS; CANCER RECURRENCE; CANCER SURVIVAL; CYTOREDUCTIVE SURGERY; EFFUSION; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; OVARIAN SEROUS CARCINOMA EFFUSION; OVARY CARCINOMA; OVARY SEROUS CARCINOMA; OVERALL SURVIVAL; PLEURA EFFUSION; PROGRESSION FREE SURVIVAL; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; SURVIVAL TIME;

BIOMARKERS; IMMUNOHISTOCHEMISTRY; OVARIAN CARCINOMA; SEROUS EFFUSIONS; SURVIVAL;

ADULT; AGED; AGED, 80 AND OVER; ANIMALS; ASCITIC FLUID; COHORT STUDIES; CYSTADENOCARCINOMA, SEROUS; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; MIDDLE AGED; NEOPLASM METASTASIS; OVARIAN NEOPLASMS; PLEURAL EFFUSION, MALIGNANT; PROGNOSIS; RETROSPECTIVE STUDIES; SURVIVAL ANALYSIS; TUMOR MARKERS, BIOLOGICAL;

EID: 84885634420     PISSN: 00468177     EISSN: 15328392     Source Type: Journal    
DOI: 10.1016/j.humpath.2013.06.003     Document Type: Article

References (44)

1. R. Siegel, D. Naishadham, and A. Jemal Cancer statistics, 2012 CA Cancer J Clin 62 2012 10 29
2. C.G. Tropé, M.B. Elstrand, B. Sandstad, B. Davidson, and H. Oksefjell Neoadjuvant chemotherapy, interval debulking surgery or primary surgery in stage IV ovarian cancer? Eur J Cancer 48 2012 2146 2154
3. B. Davidson, P. Firat, and C.W. Michael Serous effusions 2011 Springer London, UK
4. J. Prat Ovarian carcinomas: five distinct diseases with different origins, genetic alterations, and clinicopathological features Virchows Arch 460 2012 237 249
5. R. Vang, IeM Shih, and R.J. Kurman Ovarian low-grade and high-grade serous carcinoma: pathogenesis, clinicopathologic and molecular biologic features, and diagnostic problems Adv Anat Pathol 16 2009 267 282
6. E. O'Degaard, A.C. Staff, and J. Kærn AP-2γ is a marker of tumor progression in ovarian carcinoma Gynecol Oncol 100 2006 462 468
7. B. Davidson, Z. Xi, and T.I. Klokk Kallikrein 4 expression is upregulated in ovarian carcinoma cells in effusions Am J Clin Pathol 123 2005 360 368
8. B. Davidson, E. Alejandro, and V.A. Flørenes Granulin-epithelin precursor (GEP) is a novel prognostic marker in epithelial ovarian cancer Cancer 100 2004 2139 2147
9. B. Davidson, M. Bukholt Elstrand, and M.T. McMaster HLA-G expression in effusions is a possible marker of tumor susceptibility to chemotherapy in ovarian carcinoma Gynecol Oncol 96 2005 42 47
10. Y.C. Chen, G. Pohl, and T.L. Wang Apolipoprotein E is required for cell proliferation and survival in ovarian cancer Cancer Res 65 2005 331 337
11. B. Davidson, I. Shafat, N. Ilan, C.G. Trope', I. Vlodavsky, and R. Reich Heparanase expression correlates with poor survival in metastatic ovarian carcinoma Gynecol Oncol 104 2007 311 319
12. B. Davidson, R. Hadar, and A. Schlossberg Expression and clinical role of DJ-1, a negative regulator of PTEN, in ovarian carcinoma Hum Pathol 39 2008 87 95
13. B. Davidson, R. Hadar, H. Tuft Stavnes, C.G. Trope', and R. Reich Expression of the peroxisome proliferator-activated receptors (PPAR)-α, -β and -γ in ovarian carcinoma effusions is associated with poor chemoresponse and shorter survival Hum Pathol 40 2009 705 713
14. B. Davidson, C.G. Trope', T.L. Wang, and IeM Shih Expression of the chromatin remodeling factor Rsf-1 in effusions is a novel predictor of poor survival in ovarian carcinoma Gynecol Oncol 103 2006 814 819
15. B. Davidson, A. Berner, C.G. Trope', T.L. Wang, and IeM Shih Expression and clinical role of the BTB/POZ protein NAC-1 in ovarian carcinoma effusions Hum Pathol 38 2007 1030 1036
16. L. Kleinberg, V.A. Flørenes, and I. Silins Nuclear expression of survivin is associated with improved survival in metastatic ovarian carcinoma Cancer 109 2007 228 238
17. L. Kleinberg, A. Holth, C.G. Trope', R. Reich, and B. Davidson Claudin upregulation in ovarian carcinoma effusions is associated with poor survival Hum Pathol 39 2008 747 757
18. S.M. Ueda, K.L. Yap, and B. Davidson Expression of fatty acid synthase depends on NAC1 and is associated with recurrent ovarian serous carcinomas J Oncol 2010 2010 285191
19. B. Davidson, M. Baekelandt, and IeM Shih MUC4 is upregulated in ovarian carcinoma effusions and differentiates carcinoma cells from mesothelial cells Diagn Cytopathol 35 2007 756 760
20. B. Davidson, I.M. Shih, and T.L. Wang Different clinical roles for p21-activated kinase-1 in primary and recurrent ovarian carcinoma Hum Pathol 39 2008 1630 1636
21. A. Slipicevic, and I.C. Askildt The diagnostic and prognostic role of the insulin growth factor pathway members IGF-II and IGFBP3 in serous effusions Hum Pathol 40 2009 527 537
22. G.M. Mælandsmo, V.A. Flørenes, M.T.P. Nguyen, K. Flatmark, and B. Davidson Different expression and clinical role of S100A4 in ovarian carcinoma at different anatomic sites Tumor Biol 30 2009 15 25
23. M. Bunkholt Elstrand, L. Kleinberg, E.C. Kohn, C.G. Tropé, and B. Davidson Expression and clinical role of anti-apoptotic proteins of the bag, heat shock and Bcl-2 families in effusions, primary tumors and solid metastases in ovarian carcinoma Int J Gynecol Pathol 28 2009 211 221
24. L. Kleinberg, H.P. Dong, and A. Holth Cleaved caspases and NF-κB p65 are prognostic factors in metastatic ovarian carcinoma Hum Pathol 40 2009 795 806
25. N. Jinawath, C. Vasoontara, and A. Jinawath Oncoproteomic analysis reveals co-upregulation of RELA and STAT5 in carboplatin resistant ovarian carcinoma PLoS One 5 2010 e11198
26. M. Bunkholt Elstrand, H.P. Dong, and E. ∅degaard Mammalian target of rapamycin is a biomarker of poor survival in metastatic ovarian carcinoma Hum Pathol 41 2010 794 804
27. B. Davidson, A. Holth, L. Moripen, C.G. Trope', and IeM Shih Osteopontin expression in ovarian carcinoma effusions is related to improved clinical outcome Hum Pathol 42 2011 991 997
28. T.E. Hetland, E. Hellesylt, V.A. Flørenes, C.G. Tropé, B. Davidson, and J. Kærn Class III beta-tubulin expression in advanced-stage serous ovarian carcinoma effusions is associated with poor survival and primary chemoresistance Hum Pathol 42 2011 1019 1026
29. A.J. Bock, H. Tuft Stavnes, J. Kærn, A. Berner, A.C. Staff, and B. Davidson Endoglin (CD105) expression in ovarian serous carcinoma effusions is related to chemotherapy status Tumor Biol 32 2011 589 596
30. K. Brusegard, H.T. Stavnes, D.A. Nymoen, K. Flatmark, C.G. Trope', and B. Davidson Rab25 is overexpressed in Müllerian serous carcinoma compared to malignant mesothelioma Virchows Arch 460 2012 193 202
31. M.B. Elstrand, H.T. Stavnes, C.G. Tropé, and B. Davidson Heat shock protein 90 is a putative therapeutic target in patients with recurrent advanced-stage ovarian carcinoma with serous effusions Hum Pathol 43 2012 529 535
32. T.E. Hetland, A. Holth, J. Kærn, V.A. Flørenes, C.G. Tropé, and B. Davidson HMGA2 protein expression in ovarian serous carcinoma effusions, primary tumors and solid metastases Virchows Arch 460 2012 505 513
33. J.T. Thigpen, J.A. Blessing, H. Ball, S.J. Hummel, and R.J. Barrett Phase II trial of paclitaxel in patients with progressive ovarian carcinoma after platinum-based chemotherapy: a Gynecologic Oncology Group study J Clin Oncol 12 1994 1748 1753
34. P. Therasse, S.G. Arbuck, and E.A. Eisenhauer New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada J Natl Cancer Inst 92 2000 205 216
35. J.C. Mutrie, A.F. Chambers, and A.B. Tuck Osteopontin increases breast cancer cell sensitivity to specific signaling pathway inhibitors in preclinical models Cancer Biol Ther 12 2011 680 690
36. S.K. Mishra, H.R. Siddique, and M. Saleem S100A4 calcium-binding protein is key player in tumor progression and metastasis: preclinical and clinical evidence Cancer Metastasis Rev 31 2012 163 172
37. R.M. Samarasinghe, J. Gibbons, R.K. Kanwar, and J.R. Kanwar Nanotechnology based platforms for survivin targeted drug discovery Expert Opin Drug Discov 7 2012 1083 1092
38. A. Felisiak-Golabek, A. Rembiszewska, I.K. Rzepecka Polish Ovarian Cancer Study Group (POCSG) Nuclear survivin expression is a positive prognostic factor in taxane-platinum-treated ovarian cancer patients J Ovarian Res 4 2011 20
39. J.W. Kornfeld, F. Grebien, and M.A. Kerenyi The different functions of Stat5 and chromatin alteration through Stat5 proteins Front Biosci 13 2008 6237 6254
40. G. Ferbeyre, and R. Moriggl The role of Stat5 transcription factors as tumor suppressors or oncogenes Biochim Biophys Acta 2011 1815 104 114
41. S. Elloul, O. Vaksman, H.T. Stavnes, C.G. Tropé, B. Davidson, and R. Reich Mesenchymal-to-epithelial transition determinants as characteristics of ovarian carcinoma effusions Clin Exp Metastasis 27 2010 161 172
42. S. Banerjee, and S.B. Kaye New strategies in the treatment of ovarian cancer: current clinical perspectives and future potential Clin Cancer Res 19 2013 961 968
43. S.N. Westin, T.J. Herzog, and R.L. Coleman Investigational agents in development for the treatment of ovarian cancer Invest New Drugs 31 2013 213 229
44. C. Sun, T. Yi, and X. Song Efficient inhibition of ovarian cancer by short hairpin RNA targeting claudin-3 Oncol Rep 26 2011 193 200